ArticleTranslational pediatrics2025
Association between polyunsaturated fatty acid intake and allergic rhinitis in children and adolescents: a cross-sectional study of the 2007-2016 NHANES data.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is a prevalent immune-mediated disease, increasingly affecting children and adolescents. While diet is suspected to influence allergic diseases, the link between polyunsaturated fatty acids [PUFAs; omega-3 (n-3), and omega-6 (n-6)] and AR, particularly in younger populations, remains unclear. The gut microbiota's role as a potential modifier also warrants investigation. This study aims to assess the correlation between dietary PUFA intake and AR status and explore the potential involvement of gut microbiota characteristics. Methods: This cross-sectional study analyzed data from the 2007-2016 National Health and Nutrition Examination Survey (NHANES), including 994 children and adolescents (1-16 years). Dietary PUFA intake [total PUFAs (TPFAs), n-3, and n-6] was assessed using 2-day 24-hour dietary recalls. AR status was determined by self-reported physician diagnosis and symptoms in the past year. Covariates, including demographics, clinical conditions, and dietary components, were adjusted for. Gut microbiota data were obtained from an external cohort involving 16S ribosomal RNA (rRNA) sequencing of fecal samples from 24 AR patients and 25 healthy controls, focusing on the V3-V4 region. Generalized linear mixed-effects models were used to evaluate associations between PUFA intake and AR, accounting for random effects and key interactions. Results: The study included 994 participants (mean age 9 years; 46.4% male). TPFA intake was significantly associated with an increased risk of AR [odds ratio (OR) =1.02; 95% confidence interval (CI): 1.00-1.04; P=0.03]. Specifically, n-6 PUFA intake was positively associated with AR risk (OR =1.02; 95% CI: 1.00-1.04; P=0.03), with octadecadienoic acid/18:2 (OR =1.02; 95% CI: 1.01-1.03; P=0.03) and octadecatrienoic acid (OR =1.23; 95% CI: 1.02-1.49; P=0.03) showing significant effects. No significant association was found between total n-3 intake and AR. The gut microbiome in AR patients showed a higher Conclusions: Higher n-6 PUFA intake is associated with an increased risk of AR in children and adolescents and may contribute to gut microbiota dysbiosis, characterized by an elevated F/B ratio and reduced abundance of beneficial short-chain fatty acid (SCFA)-producing bacteria. N-3 PUFAs may help alleviate AR symptoms by modulating gut microbial composition and promoting anti-inflammatory responses. Dietary interventions optimizing the n-6/n-3 PUFA ratio and strategies to restore gut microbiota balance could offer potential avenues for AR prevention and management. Further research is needed to clarify causal relationships and underlying mechanisms involving PUFA intake, gut microbiota, and immune regulation in AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.